Skip to main content

Vaxart, Inc.

corporate_fare Company Profile

Vaxart, Inc.

VXRT·OTC·Life Sciences·CIK 0000072444

Vaxart, Inc. is a clinical-stage biotechnology company that develops oral recombinant vaccines. The company's primary focus is on its proprietary oral vaccine platform called Vector-Adjuvant-Antigen Standardized Technology ("VAAST"). Vaxart is developing prophylactic vaccine candidates for infectious diseases such as norovirus, coronavirus (including SARS-CoV-2, which causes COVID-19), and influenza. Additionally, the company has generated preclinical data for a therapeutic vaccine candidate aimed at cervical cancer and dysplasia caused by human papillomavirus ("HPV"). Vaxart's oral tablet vaccine candidates are designed to produce broad and lasting immune responses, including systemic, mucosal, and T cell responses, which may offer enhanced protection against certain infectious diseases and potential clinical benefits for some cancers and chronic viral infections like HPV. These tablet vaccines are also intended to provide a more efficient and convenient administration method, improve patient acceptance, and reduce distribution challenges, potentially enhancing the effectiveness of vaccination campaigns. The company's platform technology uses a vector-based approach, where a virus acts as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. Vaxart was originally incorporated in California in March 2004 as West Coast Biologicals, Inc., reincorporated in Delaware in July 2007 as Vaxart, Inc. ("Private Vaxart"), and completed a reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018.

Vaxart, Inc. (OTC:VXRT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for VXRT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Vaxart Files $300M Universal Shelf, Including New $49.7M At-The-Market Offering Amid Going Concern Warning
  • Vaxart Reports Strong 2025 Financial Turnaround with $16.3M Net Income and Extended Cash Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$237.26M
Net Income
$16.33M
Diluted EPS
$0.07
Op. Cash Flow
$7.71M
Free Cash Flow
$7.57M
Operating Income
$18.07M
Cash & Equivalents
$53.81M
Debt / Equity
0.00×
Net Margin
6.9%
Shares Outstanding
240.49M sh
Source: 10-K · filed 2026-04-30 · accession 0001437749-26-014245
$0.355 -1.39% today
52-week range · as of 2026-11-05 $0.32 – $0.8449
Market cap
$79.89M
Volume
744.8K (2.4× avg)
3-mo avg 315.9K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VXRT - Filings & News (Page 3)

VXRT
Apr 15, 2026, 8:47 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.648
Real-time Price: $0.355 info
Change: -$0.293 (-45%) info
Market Cap: $79.886M info
VXRT
Mar 12, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.737
Real-time Price: $0.355 info
Change: -$0.382 (-52%) info
Market Cap: $79.886M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets